FDA Approves Treatment of Severe Hypoglycemia That Does Not Need Reconstitution

By

FHEA Faculty

1 minute

The FDA approved Gvoke Kit for the treatment of hypoglycemia in pediatric and adult patients with diabetes 2 years of age and older. The ready-to-use, room temperature, stable liquid glucagon is administered into the lower abdomen, outer thigh, or outer upper arm, and does not require reconstitution.

Gvoke Kit is available as 1 mg/0.2 mL single-dose vial and syringe kit. Gvoke Kit contains 1 single-dose sterile syringe with markings for 0.1 mL (the pediatric 0.5-mg dose) and 0.2 mL (adult 1-mg dose), and one single-dose vial containing 0.2 mL of solution.

Gvoke is a product of Xeris Pharmaceuticals. Gvoke Kit will be available in addition to the company’s previously approved glucagon formulations, the single-dose prefilled syringe Gvoke HypoPen and the autoinjector Gvoke PFS.

Prescribing information is available.

Explore more on

Editor’s note: this post was originally published on September 29, 2021 and updated on April 23, 2024.

Related

Join our email list

Get new course alerts, newsletters and more delivered directly to your inbox

By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.